COLL Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -3.81%, SMA50 -5.55%, SMA200 15.38%). The stock’s 14-day RSI is 40.84 (neutral), while the ATR of 1.64 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -12.93% below its high and over 90.36% above its low. Average 10-day trading volume of 785.24 thousand shares is significantly above the 3-month average of 477.11 thousand, indicating heightened recent market interest.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) closed at $33.23 USD, losing -$1.51 (-4.33%) from the previous close of $34.73. The stock is currently mid-range between its 52-week high and low $23.23 and $50.79. With a market capitalization of about $1.06 billion, Collegium Pharmaceutical, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.68). Key stats such as the average daily volume over the past year has been around 489.55 thousand shares, in line with its 52-week average. Headquartered in Stoughton, MA, Collegium Pharmaceutical, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Vikram Karnani, the company employs approximately 357 people and listed since May 07, 2015. Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.

Collegium Pharmaceutical, Inc. has 31.50 million shares outstanding. The public float is 28.10 million shares, elevated short interest at 16.45% of float. This equals 4.32 million shares. The short ratio is 10.26 days. Institutional investors hold 118.66% of the float. Insiders own 1.72%. Rubric Capital Management LP holds 3.13 million shares, Ciaffoni Joseph has 275.00 thousand shares and Fleming Alison B has 148.75 thousand shares. Over the past six months, insider transactions show net selling. They sold 67.37 thousand shares across 6 transactions.

Collegium Pharmaceutical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $17.38. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of 7.7% annually over the next five years. The latest quarter delivered EPS of $0.80. The next quarter is forecast at $2.13. Next year's EPS is expected at $12.61. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $44.00. The high target offers 80.56% upside. The low target suggests 32.41% downside. The mean target is $52.62. This offers 58.35% upside. Collegium Pharmaceutical, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -57.5%. The prior quarter beat by 3.7%. Over the last six quarters, Apple has recorded several small beats. These include 3.85% in August 08, 2024.

Collegium Pharmaceutical, Inc. trades at a P/E ratio of 16.76, slightly below the S&P 500 average, with a price-to-sales ratio of 1.35 and a price-to-book ratio of 3.49 trading at moderately above to book value. The P/FCF stands at 3.22, also below market averages.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares are flat 3.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Collegium Pharmaceutical, Inc. trading at a premium to the broader market with a P/E of 16.76. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $38.30, suggesting 15.26% upside. Our AI forecast model points to short-term weakness (-13.51% over two weeks), a medium-term fall (-11.8% over three months), and a longer-term gain (27.38% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Collegium Pharmaceutical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.51%, with price expected at $28.74 by April 06, 2026, within a range of $27.27 to $30.30 3-Month Outlook: Projected fall of -11.8%, reaching $29.31 by June 19, 2026, with a range of $27.64 to $30.57. 1-Year Outlook: Projected gain of 27.38%, with price at $42.33 by March 23, 2027, within a range of $40.71 to $44.47.